Evidence map›Paper›PMID 37510123›Full record

ArticleDiagnostics (Basel, Switzerland)2023

Enhancement of Diabetic Retinopathy Prognostication Using Deep Learning, CLAHE, and ESRGAN.

Ghadah Alwakid, Walaa Gouda, Mamoona Humayun

RetractedAbstract readRetracted Publication
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ghadah AlwakidDepartment of Computer Science, College of Computer and Information Sciences, Jouf University, Sakakah 72341, Al Jouf, Saudi Arabia.ORCID 0000-0002-2708-2064
Walaa GoudaDepartment of Electrical Engineering, Faculty of Engineering at Shoubra, Benha University, Cairo 11672, Egypt.ORCID 0000-0001-6615-7658
Mamoona HumayunDepartment of Information Systems, College of Computer and Information Sciences, Jouf University, Sakakah 72341, Al Jouf, Saudi Arabia.ORCID 0000-0001-6339-2257

Funding

Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia project number 223202
6 · The paper itself

Abstract

One of the primary causes of blindness in the diabetic population is diabetic retinopathy (DR). Many people could have their sight saved if only DR were detected and treated in time. Numerous Deep Learning (DL)-based methods have been presented to improve human analysis. Using a DL model with three scenarios, this research classified DR and its severity stages from fundus images using the "APTOS 2019 Blindness Detection" dataset. Following the adoption of the DL model, augmentation methods were implemented to generate a balanced dataset with consistent input parameters across all test scenarios. As a last step in the categorization process, the DenseNet-121 model was employed. Several methods, including Enhanced Super-resolution Generative Adversarial Networks (ESRGAN), Histogram Equalization (HIST), and Contrast Limited Adaptive HIST (CLAHE), have been used to enhance image quality in a variety of contexts. The suggested model detected the DR across all five APTOS 2019 grading process phases with the highest test accuracy of 98.36%, top-2 accuracy of 100%, and top-3 accuracy of 100%. Further evaluation criteria (precision, recall, and F1-score) for gauging the efficacy of the proposed model were established with the help of APTOS 2019. Furthermore, comparing CLAHE + ESRGAN against both state-of-the-art technology and other recommended methods, it was found that its use was more effective in DR classification.

Indexed as

APTOSblindnessDeep Learningdiabetic retinopathytransfer learning

Identifiers

PMID37510123
PMCPMC10378524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.